A Two Stage Trial of lenalidomide (Revlimid) : a Phase II Study of lenalidomide as Single Agent in Asymptomatic Ovarian Cancer Patients With Increasing CA 125 in Late Relapse: Followed by a Phase I of lenalidomide in Combination With Carboplatin and Liposomal Pegylated Doxorubicin.

Trial Profile

A Two Stage Trial of lenalidomide (Revlimid) : a Phase II Study of lenalidomide as Single Agent in Asymptomatic Ovarian Cancer Patients With Increasing CA 125 in Late Relapse: Followed by a Phase I of lenalidomide in Combination With Carboplatin and Liposomal Pegylated Doxorubicin.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 05 Dec 2016

At a glance

  • Drugs Lenalidomide (Primary) ; Carboplatin; Doxorubicin liposomal
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 22 Mar 2016 Last checked against ClinicalTrials.gov record.
    • 15 Mar 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
    • 02 Jun 2015 Lenalidomide + carboplatin + doxorubicin-liposomal was not feasible at the dose and schedules evaluated, mainly due to cumulative haematologic toxicity, according to results reported at ASCO 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top